NR 3-4/2002
|
|
|
|
|
|
|
|
|
Poziom przeciwciał przeciwsiatkówkowych w
surowicy chorych na endogenne zapalenie tylnego odcinka błony naczyniowej w okresie
12-miesięcznej obserwacji
Serum antiretinal antibodies titres in patients with
endogenous posterior uveitis in 12 months follow-up period
Agnieszka Kubicka-Trząska
Z Katedry i Kliniki Okulistyki Collegium Medicum Uniwersytetu Jagiellońskiego
Kierownik: prof. dr hab. n. med. Maria Starzycka |
|
|
| Summary: |
Purpose: To evaluate changes of serum
antiretinal antibodies titres (ARA) in patients with idiopathic posterior uveitis in 12
months follow-up period.
Material and methods: 50 patients (29 women and 21 men) in age 15-70 yrs
with endogenous posterior uveitis were examined. In all cases serum ARA titres were
determined by indirect immunofluorescence test on normal monkey retina as a substrate and
FITC-labelled anti-human IgA, IgG, IgM serum (Euroimmun - Niemcy). ARA were scored in
active stage of the disease and 1, 3, 6, 12 months after the immunosuppressive therapy was
started.
Results: Before treatment in active stage of the disease, the ARA were
present in serum of 40 patients (80%). The range of serum ARA titres was 1: 10 to 1: 320.
In 10 patients (20%) the serum ARA levels were not detectable. In the last control the ARA
were detected in sera of 20% of patients in titres 1: 10 to 1: 40.
Conclusions: 1. The presence of ARA in serum of 80% patients with active
endogenous posterior uveitis indicates their involvement in the etiopathogenesis of this
disease. 2. The assessment of serum ARA in patients with idiopathic posterior can act as
an indicator of immunosuppressive therapy efficacy. 3. Serum ARA analysis is not a
specific diagnostic test for endogenous posterior uveitis because ARA can be present in
serum of patients with other ocular disorders. |
| Słowa kluczowe: |
przeciwciała przeciwsiatkówkowe, immunofluorescencja pośrednia,
endogenne zapalenie błony naczyniowej. |
| Key words: |
antiretinal antibodies, indirect immunofluorescence,
endogenous uveitis. |
|
|
|
|
|
|
